Therefore, the inhibition of ACE increases mast cell mediator releasability and, hence, autocrine mast cell activation with MCAD symptoms through the stabilization of bradykinin (57). The gene discussed is ACE; the disease is medium chain acyl-CoA dehydrogenase deficiency.